Inhibikase Therapeutics Reports $11.9 Million Net Loss for Q3 2025, Driven by Increased R&D Expenses

Inhibikase Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $11.9 million for the third quarter, compared to a loss of $5.8 million in the same period last year, marking an increase of 106.5%. For the nine months ended September 30, 2025, the net loss reached $35.5 million, up from $15.4 million in the prior year, reflecting a 130.9% increase. The company's total expenses for the quarter were $12.8 million, a substantial rise from $5.8 million in the previous year, driven primarily by increased research and development costs associated with its lead product candidate, IKT-001, aimed at treating pulmonary arterial hypertension (PAH).

The company's research and development expenses surged to $7.6 million for the third quarter, an 82.6% increase from $4.2 million in the prior year. This increase was largely attributed to heightened spending on the PAH program, which saw a $4.8 million rise in costs. In contrast, expenses related to the previously pursued risvodetinib program decreased significantly, as the company has since discontinued and outlicensed this program. Selling, general, and administrative expenses also rose sharply, totaling $5.6 million, up 242.7% from $1.6 million in the same quarter last year, primarily due to increased personnel costs and stock-based compensation.

Inhibikase's financial position showed a decline in cash and cash equivalents, which fell to $38.3 million as of September 30, 2025, down from $56.5 million at the end of 2024. The company also reported total current assets of $78.5 million, a decrease from $98.5 million at the end of the previous fiscal year. The accumulated deficit increased to approximately $129.9 million, reflecting the ongoing investment in research and development without any revenue generation, as the company has yet to commercialize any products.

Strategically, Inhibikase is preparing to initiate a Phase 2b clinical trial for IKT-001, expected to begin in the fourth quarter of 2025. This trial will involve approximately 150 patients and aims to evaluate the efficacy and safety of IKT-001 in treating PAH. The company has also engaged in discussions with the FDA regarding its Phase 3 strategy and plans to apply for orphan drug designation for IKT-001. Additionally, Inhibikase completed the acquisition of CorHepta Pharmaceuticals in February 2025, which has contributed to the increase in research and development expenses due to the write-off of in-process research and development costs.

Looking ahead, Inhibikase anticipates continued losses as it advances its clinical programs and seeks regulatory approvals. The company has indicated that it may need to raise additional capital through equity or debt financing to support its operations and development activities. As of September 30, 2025, Inhibikase believes its existing cash and marketable securities will fund its operations for at least the next twelve months, although it acknowledges the inherent uncertainties in its financial projections and operational plans.